Objective To investigate the efficacy of microbubble-enhanced sonothrombolysis on platelet-rich thrombi (PRT) and erythrocyte-rich thrombi (ERT) in different ages.Methods PRT and ERT in different ages were prepared both in vitro and in vivo of common carotid artery in rats.All the participants were divided into 8 groups with 4 in vitro and another 4 in vivo experiment,including PRT 3 h,PRT 24 h,ERT 3 h,ERT 24h in vitro groups and PRT 3 h,PRT 24 h,ERT 3 h,ERT 24 h in vivo groups.Microbubble-enhanced sonothrombolysis was carried out in both in vitro and in vivo experiments,and the ultrasonic images were collected.The components of PRT and ERT were identified by histopathological examination.The percentage increase of luminal cross sectional area and lytic ratio in vitro,and the recanalization rate and mean blood flow velocity of common carotid artery in vivo were mainly analyzed.Results After sonothrombolysis,both in vitro and in vivo experiment showed there was no statistically significant difference of the percentage increase of luminal cross sectional area ([121.12 ± 13.21]％ vs [130.09 ± 15.34]％),lytic ratio ([39.83± 7.09]％ vs [42.14±5.17]％),recanalization rate (83.33％ vs 91.67％) and blood flow velocity of common carotid artery ([0.21±0.02]m/s vs [0.22±0.01]m/s) between PRT 3 h group and ERT 3 h group (both P＞0.05).PRT 24 h group compared with EPR 24 h group,PRT 24 h group compared with PRT 3 h group,as well as ERT 24 h group compared with ERT 3 h group,the percent increase of luminal cross sectional area,lytic ratio,recanalization rate and blood flow velocity of common carotid artery reduced (all P＜0.05).Conclusion The efficacy of microbubble-enhanced sonothrombolysis on PRT and ERT in vitro and in vivo of of rat common carotid artery model decrease with the increase of thrombus age,especially for the PRT.

Objective To investigate the binding of the chemosynthetic analogue of N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) FAM-Aca-SDKP to hepatic stellate cell-T6 (HSC-T6) cells and basic physical characteristics.Methods The Ac-SDKP analogue short-peptide FAM-Aca-SDKP carrying green fluorescence was synthesized chemically.Quantitative real-time PCR was used to evaluate its effect on the secretion of HSC collagen and verify the consistency in the biological effect between FAM-Aca-SDKP and Ac-SDKP.A fluorescence microscope was used to observe the binding between FAM-Aca-SDKP and HSC-T6,and flow cytometry was used to evaluate the time-concentration effect of the binding between FAM-Aca-SDKP and HSC-T6.The t-test or rank sum test was used for the statistical analysis of different types ofdata.Results After HSC-T6 was incubated with Ac-SDKP or FAM-Aca-SDKP for 24 hours,the expression of type Ⅰ collagen in HSC-T6 was increased,when the action time was 0.5 hour,Ac-SDKP and FAM-Aca-SDKP caused a 30％-50％ reduction in the expression of type Ⅰ collagen.After HSC-T6 was incubated with FAM-Aca-SDKP,strong green fluorescence was observed on cell surface under a fluorescence microscope,and after Ac-SDKP was added,Ac-SDKP significantly reduced the fluorescence intensity on cell surface due to competitive inhibition.Flow cytometry showed that when the concentration of FAM-Aca-SDKP was 0-50 μmol/L,the rate of fluorescence-positive cells rapidly increased from 0 to 12％;when the concentration was 50-100 μmol/L,the rate of fluorescence-positive cells only increased from 12％ to 14％;co-incubation with Ac-SDKP significantly reduced the rate of fluorescence-positive cells.The number of positive cells reached the peak at the 45-minute point of the incubation and then decreased gradually.Conclusions FAM-Aca-SDKP can bind to the surface of HSC-T6 cells,and this process has ligand-receptor binding characteristics such as competitive inhibition,saturability,and time-concentration effect.

Objective To discuss the effectiveness of comprehensive intervention of cognitive behavior on the symptoms of pain , fatigue and sleep disorders for patients with advanced cancer .Methods Sixty-two patients with advanced cancer were divided into the experimental group ( n=32 ) and the control group ( n=30).The experimental group was given relaxation exercises and natural image intervention .Then the digital pain evaluation , brief fatigue inventory ( BFI ) , Pittsburgh sleep quality index ( PSQI ) and the Anderson symptom inventory ( MDASI ) were applied to analyze the differences between the experimental group and the control group.Results Pain, fatigue, poor appetite and sleep disorder were the most common symptoms , and the incidence of these symptoms were 95.1%, 92.6%, 88.5% and 86.1%, respectively.The average pain score of patients in the experimental group was (2.47 ±0.53), which was significantly lower than (5.54 ± 0.37) of patients in the control group, with a significant difference(t=2.84,P<0.01).The score of BFI for patients in the experimental group was (3.44 ±1.24), which was significantly lower than (4.92 ±0.41) of patients in the control group, with a significant difference (t=2.47,P<0.05).The score of PSQI for patients in the experimental group was (2.67 ±0.73), which was significantly lower than (5.18 ±1.09) of patients in the control group, with a significant difference (t =5.34,P <0.01).Conclusions The cognitive behavior intervention can effectively alleviate symptoms including pain , fatigue, and sleep disorder for patients with advanced cancer .

ObjectiveTo observe the clinical efficacy and safety of Modified Guomin Decoction （加味过敏煎， MGD） in patients with mild to moderate atopic dermatitis （AD） of the traditional Chinese medicine （TCM） pattern of heart fire and spleen deficiency， and to explore its possible mechanisms. MethodsIn this randomized， double-blind， placebo-controlled study， 72 patients with mild to moderate AD and the TCM pattern of heart fire and spleen deficiency were randomly divided into a treatment group and a control group， with 36 cases in each group. The treatment group received oral MGD granules combined with topical vitamin E emulsion， while the control group received oral placebo granules combined with topical vitamin E treatment. Both groups were treated twice daily for 4 weeks. Clinical efficacy， TCM syndrome scores， Visual Analogue Scale （VAS） for pruritus， Dermatology Life Quality Index （DLQI） scores， Scoring Atopic Dermatitis （SCORAD） and serum biomarkers， including interleukin-33 （IL-33）， interleukin-1β （IL-1β）， immunoglobulin E （IgE）， and tumor necrosis factor-α （TNF-α） were compared before and after treatment. Safety indexes was also assessed. ResultsThe total clinical effective rates were 77.78% （28/36） in the treatment group and 38.89% （14/36） in the control group， with cure rates of 19.44% （7/36） and 2.78% （1/36）， respectively. The treatment group showed significantly better clinical outcomes compared to the control group （P＜0.05）. The treatment group exhibited significant reductions in total TCM syndrome scores， including erythema， edema， papules， scaling， lichenification， pruritus， irritability， insomnia， abdominal distension， and fatigue scores， as well as reductions in VAS， DLQI， SCORAD， and serum IgE and IL-33 levels （P＜0.05 or P＜0.01）. Compared to the control group， the treatment group had significantly better improvements in all indicators except for insomnia （P＜0.05）. No adverse events occurred in either group. ConclusionMGD is effective and safe in treating mild to moderate AD patients with heart fire and spleen deficiency pattern. It significantly alleviates pruritus， improves TCM syndromes and quality of life， and enhances clinical efficacy， possibly through modulation of immune responses.